Skip to main content
Premium Trial:

Request an Annual Quote

Astute Medical Receives $15M Investment from Ortho-Clinical as Part of Sales and Licensing Deal

Premium

NEW YORK (GenomeWeb) – Astute Medical said this week that it has entered a strategic collaboration with Ortho-Clinical Diagnostics to expand sales of its NephroCheck test for acute kidney injury.

Under the agreement, in exchange for a $15 million equity investment from OCD, Astute has made the company the exclusive sales agent for NephroCheck and the Astute 140 Meter device on which the test is performed in portions of the EU and, upon regulatory approval, in the US.

Astute has also granted OCD a semi-exclusive global license to develop and commercialize a version of NephroCheck for use on OCD's Vitros line of automated testing platforms.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.